Notable Stock to Watch: Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS)

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) spotted trading -73.46% off 52-week high price. On the other end, the stock has been noted 245.00% away from the low price over the last 52-weeks. The stock changed 6.15% to recent value of $0.69. The stock transacted 3585301 shares during most recent day however it has an average volume of 974.65K shares. The company has 66.99M of outstanding shares and 66.99M shares were floated in the market.  

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) reported the promotion of Judy Fox, Ph.D. from Chief Scientific Officer, Senior Vice President to Chief Scientific Officer, Executive Vice President, Research & Development and the promotion of Parvinder (Par) S. Hyare from Vice President, Global Oncology Operations to Senior Vice President, Commercial.

Dayton Misfeldt, Interim Chief Executive Officer of Sunesis said “Judy and Par are accomplished leaders who have each made invaluable contributions to our programs, most recently with vecabrutinib. I am pleased to announce these well-deserved promotions, and we look forward to their continued leadership as we prepare for the next stage of our company’s growth,”. “We are seeing great momentum in our ongoing Phase 1b/2 trial towards determining the recommended dose for the Phase 2 expansion and are well prepared for the transition into this phase of the trial. We are targeting our next detailed clinical update at the annual American Society of Hematology meeting later this year.”

Dr. Fox rejoined Sunesis in 2017 as Chief Scientific Officer and program leader for vecabrutinib, with additional responsibility for much of the R&D organization including translational research and clinical development. She has contributed to the development of a number of promising and marketed therapeutics, and has held roles of increasing responsibility at companies including Genentech, Genencor, and Chiron/Novartis. Dr. Fox received her Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology, and an A.B. in Chemistry from Bryn Mawr College.

Mr. Hyare joined Sunesis in July 2014 with extensive experience in leading commercial strategies and teams to provide pricing, reimbursement, access and sales for oncology and specialty products for companies such as AMAG Pharmaceuticals, Ortho Biotech, a division of Johnson & Johnson, and Merck. At Sunesis, Mr. Hyare has had responsibility for many areas including commercial planning, strategic marketing, medical affairs, and business development. Mr. Hyare holds a BS in Business Administration with a minor in chemistry from CSU Stanislaus.

 Its earnings per share (EPS) expected to touch remained 48.30% for this year . SNSS .   According to the most recent quarter its current ratio was 2.6 that represents company’s ability to meet its current financial obligations. The price moved ahead of 0.76% from the mean of 20 days, -27.98% from mean of 50 days SMA and performed -32.09% from mean of 200 days price. Company’s performance for the week was -5.06%, -1.43% for month and YTD performance remained 65.99%.

Leave a Reply

Your email address will not be published. Required fields are marked *